KalVista Pharmaceuticals, Inc.

NasdaqGM:KALV 주식 보고서

시가총액: US$533.3m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

KalVista Pharmaceuticals 소유권

주요 주주는 누구이며 내부자가 매수 또는 매도한 적이 있나요?

최근 내부자 거래

NasdaqGM:KALV 회사 또는 개인의 최근 내부자 거래
날짜가치이름엔티티역할공유최대 가격
28 Mar 24SellUS$14,905,154TCG Crossover Management, LLCCompany1,355,014US$11.00
20 Feb 24BuyUS$999,988Frazier Life Sciences Management, LPCompany65,573US$15.25
16 Feb 24SellUS$13,151,726TCG Crossover Management, LLCCompany877,125US$16.22
14 Feb 24SellUS$598,661Christopher YeaIndividual39,886US$15.01
14 Feb 24SellUS$422,827Edward FeenerIndividual28,171US$15.01
14 Feb 24SellUS$875,883Thomas CrockettIndividual58,356US$15.01
14 Feb 24SellUS$613,205Benjamin PalleikoIndividual40,855US$15.01
08 Feb 24BuyUS$1,257,829VR Adviser, LLCCompany86,048US$14.74
30 Jan 24BuyUS$1,274,793VR Adviser, LLCCompany88,099US$14.47
25 Jan 24BuyUS$89,492VR Adviser, LLCCompany7,030US$12.73
24 Jan 24BuyUS$1,241,685VR Adviser, LLCCompany99,129US$12.55
19 Jan 24BuyUS$1,801,602VR Adviser, LLCCompany143,605US$12.60
16 Jan 24BuyUS$333,779VR Adviser, LLCCompany26,246US$12.73
10 Jan 24BuyUS$1,726,457VR Adviser, LLCCompany137,700US$12.67
04 Jan 24BuyUS$720,543VR Adviser, LLCCompany59,369US$12.20
29 Dec 23BuyUS$6,465,650VR Adviser, LLCCompany519,017US$12.50
12 Dec 23BuyUS$2,972,278Frazier Life Sciences Management, LPCompany343,435US$9.53

내부자 거래량

내부자 구매: 내부자가 지난 3개월 동안 판매한 것보다 더 많은 주식을 구입했는지 판단하기에는 데이터가 부족합니다.

소유권 분석

KALV 의 소유 구조는 어떻게 되나요?
소유자 유형공유 수소유권 비율
개인 내부자704,2821.44%
헤지 펀드6,492,00513.2%
VC/PE 기업9,937,59820.2%
교육기관31,944,66265.1%

주식의 희석: 지난 해 주주 수는 희석되었으며, 총 발행 주식 수 24.7% 만큼 증가했습니다.

최대 주주

상위 25 주주가 회사의 101.99%를 소유하고 있습니다.
소유권이름공유현재 값변경 %포트폴리오 %
14.5%
VR Adviser, LLC
6,249,731US$77.1m0%2.54%
9.76%
Tang Capital Management, LLC
4,218,829US$52.1m2.27%3.7%
9.7%
Suvretta Capital Management, LLC
4,192,005US$51.7m0%1.55%
8.53%
Frazier Life Sciences Management, LP
3,687,867US$45.5m0%1.54%
7.47%
Capital Research and Management Company
3,227,620US$39.8m120%데이터 없음
6.81%
BlackRock, Inc.
2,945,116US$36.3m21.1%데이터 없음
5.32%
Vestal Point Capital, LP
2,300,000US$28.4m251%1.55%
4.74%
Adage Capital Management, L.P.
2,050,000US$25.3m-20.4%0.04%
4.61%
The Vanguard Group, Inc.
1,990,588US$24.6m18.1%데이터 없음
3.68%
Tavistock Life Sciences
1,590,000US$19.6m0%0.8%
3.1%
Great Point Partners, LLC
1,338,568US$16.5m0%2.54%
2.71%
Emerald Advisers, LLC
1,173,262US$14.5m-2.27%0.26%
2.61%
Saturn V Capital Management LP
1,128,478US$13.9m-21.7%3.99%
2.45%
First Turn Management, LLC
1,059,540US$13.1m-10.2%1.66%
2.04%
BioImpact Capital LLC
881,937US$10.9m15.9%1.37%
1.87%
Dafna Capital Management, LLC
806,973US$10.0m0%1.91%
1.87%
Geode Capital Management, LLC
806,271US$9.9m23.7%데이터 없음
1.75%
State Street Global Advisors, Inc.
756,430US$9.3m27.3%데이터 없음
1.7%
StemPoint Capital LP
736,765US$9.1m-36.5%2.08%
1.3%
Silverarc Capital Management, LLC
560,883US$6.9m-0.05%1.38%
1.24%
Driehaus Capital Management LLC
535,717US$6.6m-1.07%0.03%
1.24%
Dimensional Fund Advisors LP
534,979US$6.6m-7.71%데이터 없음
1.16%
Perceptive Advisors LLC
500,000US$6.2m0%0.11%
1.08%
Schroder Investment Management Limited
467,998US$5.8m83.7%데이터 없음
0.78%
Rosalind Advisors, Inc.
337,985US$4.2m17.4%2.33%